Published in Haematologica on February 17, 2006
Development of cell-cycle inhibitors for cancer therapy. Curr Oncol (2009) 1.57
Dinaciclib, a novel CDK inhibitor, demonstrates encouraging single-agent activity in patients with relapsed multiple myeloma. Blood (2014) 1.12
Phase I trial of bortezomib (PS-341; NSC 681239) and alvocidib (flavopiridol; NSC 649890) in patients with recurrent or refractory B-cell neoplasms. Clin Cancer Res (2011) 1.02
Cyclin-dependent kinase inhibitor therapy for hematologic malignancies. Expert Opin Investig Drugs (2013) 0.96
Targeting MET transcription as a therapeutic strategy in multiple myeloma. Cancer Chemother Pharmacol (2008) 0.91
A phase I clinical trial of FOLFIRI in combination with the pan-cyclin-dependent kinase (CDK) inhibitor flavopiridol. Cancer Chemother Pharmacol (2010) 0.88
A phase I trial of flavopiridol in relapsed multiple myeloma. Cancer Chemother Pharmacol (2013) 0.84
Implication of transcriptional repression in compound C-induced apoptosis in cancer cells. Cell Death Dis (2013) 0.79
A combination of cisplatin-eluting gelatin microspheres and flavopiridol enhances anti-tumour effects in a rabbit VX2 liver tumour model. Br J Radiol (2009) 0.79
Sangivamycin-like molecule 6 exhibits potent anti-multiple myeloma activity through inhibition of cyclin-dependent kinase-9. Mol Cancer Ther (2012) 0.78
Potent anti-tumor activity of a macrocycle-quinoxalinone class pan-Cdk inhibitor in vitro and in vivo. Invest New Drugs (2010) 0.78
Phase I trial of bortezomib (PS-341; NSC 681239) and "nonhybrid" (bolus) infusion schedule of alvocidib (flavopiridol; NSC 649890) in patients with recurrent or refractory indolent B-cell neoplasms. Clin Cancer Res (2014) 0.78
Combining proteasome with cell cycle inhibitors: a dual attack potentially applicable to multiple hematopoietic malignancies. Expert Rev Hematol (2011) 0.78
Anticancer Alkaloids from Trees: Development into Drugs. Pharmacogn Rev (2017) 0.75
Initial genome sequencing and analysis of multiple myeloma. Nature (2011) 17.28
Improved survival in multiple myeloma and the impact of novel therapies. Blood (2007) 12.70
Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc (2003) 9.96
Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma. Cancer Cell (2007) 7.24
Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol (2005) 6.98
Pilot study using molecular profiling of patients' tumors to find potential targets and select treatments for their refractory cancers. J Clin Oncol (2010) 6.34
Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. N Engl J Med (2007) 6.07
Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. Blood (2005) 5.82
Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol (2009) 5.73
Prevalence and risk of progression of light-chain monoclonal gammopathy of undetermined significance: a retrospective population-based cohort study. Lancet (2010) 4.75
In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. Mayo Clin Proc (2015) 4.70
Clonal competition with alternating dominance in multiple myeloma. Blood (2012) 4.39
POEMS syndrome: definitions and long-term outcome. Blood (2002) 4.35
Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Semin Oncol (2003) 3.88
Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study. Lancet Oncol (2010) 3.75
Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide. Blood (2011) 3.58
Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis. J Clin Oncol (2004) 3.43
Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma. J Clin Oncol (2005) 3.41
New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. J Clin Oncol (2012) 3.35
Genomic abnormalities in monoclonal gammopathy of undetermined significance. Blood (2002) 3.34
Phase II study of erlotinib in patients with advanced biliary cancer. J Clin Oncol (2006) 3.31
Association of Clinical Researchers and Educators a statement on relationships between physicians and industry. Endocr Pract (2012) 3.27
Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2. Blood (2011) 3.07
Role of cardiac magnetic resonance imaging in the detection of cardiac amyloidosis. JACC Cardiovasc Imaging (2010) 3.03
Whole-genome sequencing of multiple myeloma from diagnosis to plasma cell leukemia reveals genomic initiating events, evolution, and clonal tides. Blood (2012) 2.98
Superior survival in primary systemic amyloidosis patients undergoing peripheral blood stem cell transplantation: a case-control study. Blood (2004) 2.97
Mayo clinic consensus statement for the use of bisphosphonates in multiple myeloma. Mayo Clin Proc (2006) 2.88
Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma. Blood (2007) 2.87
Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines. Mayo Clin Proc (2009) 2.86
Complementary and alternative medicine use among long-term lymphoma survivors: a pilot study. Am J Hematol (2009) 2.84
AID-dependent activation of a MYC transgene induces multiple myeloma in a conditional mouse model of post-germinal center malignancies. Cancer Cell (2008) 2.84
Amyloidosis: pathogenesis and new therapeutic options. J Clin Oncol (2011) 2.82
American Thyroid Association guidelines for management of patients with anaplastic thyroid cancer. Thyroid (2012) 2.71
Myeloid cell factor-1 is a critical survival factor for multiple myeloma. Blood (2002) 2.68
Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer. J Clin Oncol (2005) 2.65
Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. J Clin Oncol (2002) 2.63
Clinical course of patients with relapsed multiple myeloma. Mayo Clin Proc (2004) 2.62
Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013. Mayo Clin Proc (2013) 2.59
Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancer. J Clin Oncol (2005) 2.56
Treatment of newly diagnosed multiple myeloma based on Mayo Stratification of Myeloma and Risk-adapted Therapy (mSMART): consensus statement. Mayo Clin Proc (2007) 2.55
Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and -17p13 in myeloma patients treated with high-dose therapy. Blood (2005) 2.54
Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma. J Clin Oncol (2009) 2.50
Current therapy for multiple myeloma. Mayo Clin Proc (2002) 2.47
Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory disease. Blood (2011) 2.45
Stem cell transplantation in multiple myeloma: impact of response failure with thalidomide or lenalidomide induction. Blood (2010) 2.40
Long-term results of response to therapy, time to progression, and survival with lenalidomide plus dexamethasone in newly diagnosed myeloma. Mayo Clin Proc (2007) 2.34
The outcome of combined-modality therapy for stage III non-small-cell lung cancer in the elderly. J Clin Oncol (2003) 2.32
CD49d expression is an independent predictor of overall survival in patients with chronic lymphocytic leukaemia: a prognostic parameter with therapeutic potential. Br J Haematol (2008) 2.29
Subcutaneous interleukin-4 (IL-4) for relapsed and resistant non-Hodgkin lymphoma: a phase II trial in the North Central Cancer Treatment Group, NCCTG 91-78-51. Leuk Lymphoma (2007) 2.20
Molecular dissection of hyperdiploid multiple myeloma by gene expression profiling. Cancer Res (2007) 2.19
The recurrent IgH translocations are highly associated with nonhyperdiploid variant multiple myeloma. Blood (2003) 2.12
Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple myeloma: a comparative analysis of 411 patients. Blood (2009) 2.12
Eliminating the complete response penalty from myeloma response assessment. Blood (2008) 2.11
Monoclonal gammopathy of undetermined significance does not affect outcomes in patients undergoing solid organ transplants. Transplantation (2011) 2.10
Dronabinol versus megestrol acetate versus combination therapy for cancer-associated anorexia: a North Central Cancer Treatment Group study. J Clin Oncol (2002) 2.09
Temsirolimus and rituximab in patients with relapsed or refractory mantle cell lymphoma: a phase 2 study. Lancet Oncol (2011) 2.03
Ectopic expression of VAV1 reveals an unexpected role in pancreatic cancer tumorigenesis. Cancer Cell (2005) 2.01
Importance of achieving stringent complete response after autologous stem-cell transplantation in multiple myeloma. J Clin Oncol (2013) 2.01
The cyclin-dependent kinase inhibitor flavopiridol induces apoptosis in multiple myeloma cells through transcriptional repression and down-regulation of Mcl-1. Clin Cancer Res (2002) 1.99